Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma — Stella

Recruiting

Back to Mantle Cell Lymphoma trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

Trial locations(2 sites)

United States

University of California, Davis, Davis, California

University of California, San Francisco, San Francisco, California

Key details

Phase

Safety & dosing

Sponsor

University of California, San Francisco

Collaborators

Eli Lilly and Company, Genentech, Inc.

Enrollment target

~30 participants

Started

June 2024

Primary completion

July 2028

Age range

18 Years and older

Last updated October 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov